Congress quietly expands health subsidies while imposing strict new rules on drug middlemen.
H.R. 6575 — CommonGround for Affordable Health Care Act · Filed by Jennifer Kiggans (R-VA) · 38 cosponsors · Introduced Dec 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends and expands the Affordable Care Act's premium tax credits (subsidies) through 2026, allowing more middle-income households to qualify and capping their premium contributions at lower percentages of income. It also establishes new fraud-prevention rules for health insurance agents and brokers, creates oversight of pharmacy benefit managers (PBMs) in Medicare Part D to increase transparency and limit hidden fees, and extends the ACA open enrollment period for 2026.
Why we flagged it
The bill's primary function is to extend and liberalize ACA premium subsidies while imposing new transparency and anti-fraud rules on pharmacy benefit managers and insurance agents. These are distinct policy objectives bundled together.
What the text implies
- The extended premium tax credits (up to 1000% of poverty line by 2026) may create a 'subsidy cliff' when the temporary provision expires, potentially destabilizing the individual market in 2027 if not renewed.
- PBM transparency requirements impose significant reporting burdens (detailed drug-by-drug data, affiliate disclosures, audit rights) that may consolidate the PBM market toward larger, better-resourced firms and reduce competition.
The full analysis lists 5 implications of this text.
Who stands to gain
Lower-income and middle-income households (via expanded premium tax credits); Pharmacy benefit managers (via clarity on compliant fee structures, though with new compliance costs; Health insurance issuers (via reduced adverse selection from broader subsidies)